Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13)

Isabel Carbery,Gemma Burdge,Tanya Clark,Giacomo Broglio,Dan Greer,Alaa Alakkari,Christian Philipp Selinger

doi:10.1136/bmjgast-2023-001105

Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13)

Isabel Carbery, Gemma Burdge + Show 5 more

Open Access

https://doi.org/10.1136/bmjgast-2023-001105

Copy DOI

Journal: BMJ Open Gastroenterology	Publication Date: Feb 1, 2023
Citations: 3	License type: open-access

Affiliation: Leeds Teaching Hospitals NHS Trust, Policlinico San Matteo Fondazione, Istituti di Ricovero e Cura a Carattere Scientifico

#Subcutaneous #Indirect Costs Of Patients + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

BackgroundWe aim to compare the real-life direct and indirect costs of switching patients from intravenous to subcutaneous (SC) CT-P13, an infliximab biosimilar, in a tertiary UK Inflammatory Bowel Disease (IBD)...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

More From: BMJ Open Gastroenterology

Paper Title

Journal

Date

Author

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.